Mackenzie Financial
FOLD

Mackenzie Financial’s Amicus Therapeutics FOLD Stock Holding History

Mackenzie Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,446
Closed -$248K – 1538
2025
Q4 		$248K Sell
17,446
-130,324
-88% -$1.28M ﹤0.01% 1454
2025
Q3 		$1.16M Buy
147,770
+8,563
+6% +$60.9K ﹤0.01% 1029
2025
Q2 		$798K Buy
139,207
+96,602
+227% +$623K ﹤0.01% 1076
2025
Q1 		$348K Buy
42,605
+20,107
+89% +$186K ﹤0.01% 1330
2024
Q4 		$212K Sell
22,498
-6,379
-22% -$66.3K ﹤0.01% 1543
2024
Q3 		$308K Buy
28,877
+1,678
+6% +$18.3K ﹤0.01% 1172
2024
Q2 		$270K Buy
27,199
+191
+0.7% +$1.96K ﹤0.01% 1208
2024
Q1 		$318K Sell
27,008
-2,049
-7% -$26.2K ﹤0.01% 1151
2023
Q4 		$412K Buy
29,057
+4,260
+17% +$48.4K ﹤0.01% 1053
2023
Q3 		$274K Sell
24,797
-18,672
-43% -$241K ﹤0.01% 1170
2023
Q2 		$534K Sell
43,469
-7,711
-15% -$91.5K ﹤0.01% 999
2023
Q1 		$568K Buy
51,180
+8,490
+20% +$105K ﹤0.01% 988
2022
Q4 		$521K Sell
42,690
-14,561
-25% -$164K ﹤0.01% 916
2022
Q3 		$598K Sell
57,251
-21,376
-27% -$238K ﹤0.01% 894
2022
Q2 		$844K Buy
78,627
+20,750
+36% +$171K ﹤0.01% 860
2022
Q1 		$548K Sell
57,877
-332
-0.6% -$3.11K ﹤0.01% 973
2021
Q4 		$672K Sell
58,209
-1,026
-2% -$11.4K ﹤0.01% 957
2021
Q3 		$566K Buy
59,235
+6,513
+12% +$66.6K ﹤0.01% 979
2021
Q2 		$508K Buy
52,722
+16,046
+44% +$157K ﹤0.01% 978
2021
Q1 		$362K Buy
36,676
+17,105
+87% +$265K ﹤0.01% 998
2020
Q4 		$452K Sell
19,571
-39,714
-67% -$812K ﹤0.01% 859
2020
Q3 		$837K Buy
59,285
+17,460
+42% +$254K ﹤0.01% 704
2020
Q2 		$631K Buy
+41,825
New +$510K ﹤0.01% 761

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Mackenzie Financial's FOLD Position: Q1 2026 in Review

Mackenzie Financial sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 17,446 shares — an estimated $248K sold.

Mackenzie Financial first reported a position in FOLD in Q2 2020 and held it in 23 quarters. The position peaked at $1.16M in Q3 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Mackenzie Financial reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 17,446 Amicus Therapeutics shares in Q1 2026, an estimated $248K.
  • Mackenzie Financial first reported a position in Amicus Therapeutics in Q2 2020 and held it in 23 quarters.
  • Mackenzie Financial's Amicus Therapeutics position peaked at $1.16M in Q3 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.